Organization, Basis of Presentation and Liquidity (Tables)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Lineage’s Ownership of Outstanding Shares of its Subsidiaries

  

Subsidiary  Field of Business 

Lineage

Ownership

   Country 
Asterias BioTherapeutics, Inc.(1)  Cell based therapeutics to treat neurological conditions and cancer   100%   USA 
Cell Cure Neurosciences Ltd (“Cell Cure”)  Manufacturing of Lineage’s cell replacement platform technology   99%(2)   Israel 
ES Cell International Pte. Ltd. (“ESI”) (3)  Research and clinical grade cell lines   100%   Singapore 
OrthoCyte Corporation (“OrthoCyte”) 

Research in orthopedic diseases and injuries

   99.8%   USA 

 

(1) Asterias was acquired by Lineage in March 2019.
   
(2)

Includes shares owned by Lineage and ESI.

   
(3) The operating activities and fields of business listed under these subsidiaries are conducted primarily by Lineage as the parent company.